Department of Clinical Genetics, Royal North Shore Hospital, Sydney, NSW, Australia.
NSLHD Familial Cancer Service, Department of Cancer Services, Royal North Shore Hospital, Sydney, NSW, Australia.
Fam Cancer. 2022 Apr;21(2):241-253. doi: 10.1007/s10689-021-00259-9. Epub 2021 May 8.
Women with neurofibromatosis type 1 (NF1) have an increased risk of developing early breast cancer with a poorer prognosis compared to the general population. Therefore, international management guidelines recommend regular screening in women with NF1 starting from 30 to 35 years. As the psychological impacts of breast cancer screening in other high-risk populations cannot be extended to women with NF1, due to increased incidence of cognitive and mental health issues, the psychological harms of breast screening in women with NF1 are unknown. Consequently, the aim of this study was to assess the psychological impact of breast cancer screening in women with NF1 attending an established risk management clinic. Twenty-eight women with NF1 (30-50 years) completed psychological well-being and patient experience questionnaires, administered across five time points, before and after their initial and second round annual breast screening visits. Preliminary findings demonstrated the screening regimen was well-tolerated, with most participants reporting high satisfaction with the screening process. Overall, no significant increase in psychological distress related to the breast screening process was identified, with mean cancer worry and anxiety scores decreasing over time. However, some women did experience negative aspects of screening and barriers to re-attendance at annual breast screening appointments. As some women with NF1 exhibited clinical levels of psychological distress prior to screening, efforts to identify those at risk and additional support to address concerns and expectations throughout the breast screening process may be beneficial.
患有神经纤维瘤病 1 型(NF1)的女性发生早期乳腺癌的风险增加,且预后较一般人群更差。因此,国际管理指南建议 NF1 女性从 30 至 35 岁开始进行定期筛查。由于认知和心理健康问题的发生率增加,其他高危人群乳腺癌筛查的心理影响不能推广到 NF1 女性,因此,NF1 女性乳腺癌筛查的心理危害尚不清楚。因此,本研究旨在评估在已建立的风险管理诊所就诊的 NF1 女性进行乳腺癌筛查的心理影响。28 名 NF1 女性(30-50 岁)在接受初始和第二轮年度乳房筛查前后,在五个时间点完成了心理健康和患者体验问卷调查。初步结果表明,该筛查方案具有良好的耐受性,大多数参与者对筛查过程表示高度满意。总体而言,未发现与乳房筛查过程相关的心理困扰显著增加,癌症担忧和焦虑评分随时间逐渐降低。然而,一些女性确实经历了筛查的负面方面和参加年度乳房筛查预约的障碍。由于一些 NF1 女性在筛查前表现出临床水平的心理困扰,因此,努力识别那些有风险的人,并在整个乳房筛查过程中提供额外的支持以解决问题和期望,可能会有所帮助。